Journal of Clinical Oncology
Articles in this Issue
Iparomlimab and tuvonralimab combined with paclitaxel and cisplatin as neoadjuvant therapy for cervical cancer: A phase II umbrella trial.
TPS5629 Background: There is an urgent need to improve neoadjuvant therapy for locally advanced cervical cancer (LACC) and...
Disparities in pancreatic cancer incidence and shifting survival trends in the United States (1999–2021).
e16432 Background: Pancreatic cancer remains among the most lethal malignancies in the United States, withpersistently hig...
Impact of chronic kidney disease on adverse event topography and economic burden in CAR T-cell therapy for DLBCL: A national analysis.
e19054 Background: Chronic kidney disease (CKD) may potentiate toxicity and impair organ resilience in recipients of chime...
Role of FNDC1 and Gβ2 in suppression of the β-catenin destruction complex and promotion of gastric cancer malignancy.
e16478 Background: Gastric cancer (GC) is a leading cause of cancer-related deaths with high recurrence rates. Fibronectin...
Uncovering genetic susceptibility to second malignant neoplasms in children and young adults: Findings from a tertiary oncology center in a resource-limited setting.
e22638 Background: Second malignant neoplasms (SMNs) represent a major cause of non-relapse mortality among long-term canc...
Nationwide trends in mortality with concurrent colorectal cancer and chronic ischemic heart disease: A CDC WONDER analysis (1999–2020).
e15721 Background: Co-mortality from colorectal cancer (CRC) and chronic ischemic heart disease (CIHD) is increasingly rel...
Bulumtatug fuvedotin (BFv; 9MW2821) plus toripalimab in patients with locally advanced or metastatic urothelial carcinoma (la/mUC): Follow-up results from a phase 1b/2 study.
4518 Background: Nectin-4 is an adhesion molecule that is highly expressed in variety of solid tumors, especially in uroth...
Intracranial activity of sacituzumab govitecan in HER2-negative breast cancer brain metastases: A systematic review and meta-analysis.
e14009 Background: Patients with HER2-negative metastatic breast cancer who develop brain metastases face a critical thera...
Efficacy and safety of surufatinib combined with immune checkpoint inhibitors plus chemotherapy in patients with biliary tract cancers: A real-world study.
e16222 Background: The management of advanced biliary tract cancers (BTC) remains a significant clinical challenge. Althou...
Cancer outcomes, screening rates, and health behaviors by county-level poverty status.
e23128 Background: Persistent poverty is associated with enduring structural barriers to cancer prevention and care, a cha...
First-in-world oral solution formulation of enzalutamide: Bioequivalence versus soft-gel capsule to support patient-centric drug delivery.
e17072 Background: Enzalutamide is a standard therapy for advanced prostate cancer. An oral solution formulation has been...
Unmasking the clinical impact of SGLT-2 inhibitors in stage IV colorectal cancer: A real-world multicenter analysis.
e15628 Background: Colorectal cancer (CRC) is the fourth most diagnosed cancer in the United States, and stage IV CRC has...
Transfusion effectiveness and clinical outcomes in acute leukemia: Do poor responders have worse outcomes?
e18614 Background: Transfusion support is essential for patients with acute myeloid leukemia (AML) and acute lymphoblastic...
An interpretable machine learning model using routine clinicopathological variables to predict postoperative recurrence in early-stage NSCLC: Development and external validation.
e20053 Background: Recurrence risk after curative-intent surgery in early-stage (I–II) NSCLC remains heterogeneous. We dev...
Breast cancer expanded multigene panel testing in hereditary cancer patients, from the Baja California, Mexico–USA border region.
e12513 Background: Hereditary cancer syndromes account for approximately 5–10% of all cancer cases. Germline pathogenic va...
Perceived financial barriers and delayed hospital care for breast and cervical cancer in Nigeria: A qualitative study.
e13522 Background: Breast and cervical cancers are leading causes of cancer-related morbidity and mortality in Nigeria, wi...
Financial vulnerability among U.S. cancer survivors: Differences by veteran status and VA health care utilization in the National Health Interview Survey, 2020–2024.
1561 Background: Current national comparisons of financial factors affecting cancer care among Veterans and non-Veteran ad...
Outcomes of infectious workup and antibiotic use during tarlatamab initiation in patients with advanced neuroendocrine carcinomas.
e23307 Background: Tarlatamab has improved outcomes in extensive-stage small cell lung cancer (ES-SCLC) and is under inves...
Correlation of immune remodeling linked to obesity with immunotherapy outcomes in cholangiocarcinoma: An externally validated international cohort study.
4134 Background: Obesity is an established risk factor for cancer, yet paradoxically may be associated with improved respo...
Long-term survivorship rates among previously treated advanced melanoma patients achieving objective response (OR) with lifileucel.
9592 Background: Durability of response and associated long-term survival benefits of modern cancer therapies are often ma...
Early immune recovery during adjuvant anti–PD-1 as a predictor of early recurrence in resected stage II–III melanoma.
e21545 Background: Early identification of patients at risk of recurrence during adjuvant anti–PD-1 remains an unmet need....
Clinical validation of an AI-based prognostic assay for stage I-II cutaneous melanoma.
9578 Background: In early-stage cutaneous melanoma (CM), AJCC staging demonstrates limited ability to identify patients at...
Actionable genomic alterations and survival in <i>KRAS</i> wild-type pancreatic ductal adenocarcinoma: Analysis of the MSK-CHORD 2024 clinico-genomic cohort with spotlight on <i>NRG1</i> fusions.
4222 Background: Pancreatic ductal adenocarcinoma (PDAC) is predominantly driven by KRAS mutations; however, approximately...
Randomized phase III study of nivolumab after surgery and adjuvant chemotherapy in NSCLC (ECOG-ACRIN EA5142, ALCHEMIST).
8000 Background: The NCI’s ALCHEMIST program has screened thousands of patients with resected lung adenocarcinoma...
PTHrP-associated gene programs in cancer cachexia and hypercalcemia and therapeutic targeting with anti-PTHrP antibody.
e16413 Background: Parathyroid hormone-related protein (PTHrP), a ligand of parathyroid hormone receptor-1 (PTH1R) encoded...